Alpha 2.0
Login Register
» Articles » PMID: 6487486

Atenolol Pharmacokinetics in Patients on Continuous Ambulatory Peritoneal Dialysis

Overview
Journal Br J Clin Pharmacol
Specialty Pharmacology
Date 1984 Sep 1
PMID 6487486
Citations 6
Authors
A K Salahudeen
R Wilkinson
J Mcainsh
D N Bateman
Affiliations
Soon will be listed here.
Abstract

The elimination of atenolol (20 mg i.v.) has been studied in seven patients with renal failure on continuous ambulatory peritoneal dialysis (CAPD). Although atenolol was eliminated in the peritoneal fluid, the amount recovered in 24 h was relatively low (1.2 +/- 0.15 mg). The calculated urinary (n = 4) and peritoneal (n = 7) clearance was 0.289 +/- 0.058 l/h and 0.152 +/- 0.018 l/h respectively. This was considerably less than calculated total body clearance (1.21 +/- 0.086 l/h). The kinetics of atenolol in CAPD are worthy of further study.

Citing Articles

Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Bouchard J, Shepherd G, Hoffman R, Gosselin S, Roberts D, Li Y Crit Care. 2021; 25(1):201.

PMID: 34112223 PMC: 8194226. DOI: 10.1186/s13054-021-03585-7.

Pharmacokinetic and pharmacodynamic modelling of atenolol in rabbits maintained on continuous peritoneal dialysis.

Celardo A, Traina G, Arboix M, Puigdemont A, Bonati M Eur J Drug Metab Pharmacokinet. 1987; 12(1):41-8.

PMID: 3609072 DOI: 10.1007/BF03189860.

Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.

Bonati M, Traina G, Gentile M, Fellin G, Rosina R, Cavenaghi L Br J Clin Pharmacol. 1988; 25(6):761-5.

PMID: 2974299 PMC: 1386456. DOI: 10.1111/j.1365-2125.1988.tb05265.x.

Teicoplanin pharmacokinetics in patients with chronic renal failure.

Bonati M, Traina G, Villa G, Salvadeo A, Gentile M, Fellin G Clin Pharmacokinet. 1987; 12(4):292-301.

PMID: 2954735 DOI: 10.2165/00003088-198712040-00003.

Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.

Traina G, Gentile M, Fellin G, Rosina R, Cavenaghi L, BUNIVA G Eur J Clin Pharmacol. 1986; 31(4):501-4.

PMID: 2949981 DOI: 10.1007/BF00613532.

References
1.
SCALES B, Copsey P . The gas chromatographic determination of atenolol in biological samples. J Pharm Pharmacol. 1975; 27(6):430-3. DOI: 10.1111/j.2042-7158.1975.tb09473.x. View
2.
REEVES P, Mcainsh J, MCINTOSH D, Winrow M . Metabolism of atenolol in man. Xenobiotica. 1978; 8(5):313-20. DOI: 10.3109/00498257809060956. View
3.
Mason W, Winer N, Kochak G, Cohen I, Bell R . Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther. 1979; 25(4):408-15. DOI: 10.1002/cpt1979254408. View
4.
Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A . Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. Br J Clin Pharmacol. 1980; 9(4):379-85. PMC: 1429992. DOI: 10.1111/j.1365-2125.1980.tb01065.x. View
5.
Mcainsh J, Holmes B, Smith S, Hood D, Warren D . Atenolol kinetics in renal failure. Clin Pharmacol Ther. 1980; 28(3):302-9. DOI: 10.1038/clpt.1980.166. View